Social Media is not a Health Proxy: Differences Between Social Media and Electronic Health Record Reports of Post-COVID Symptoms

The COVID-19 pandemic transformed many aspects of health and daily life. A subset of people who were infected with the virus have ongoing chronic health issues that range in type of symptom and severity. In this study, we conducted a qualitative assessment of self-reported post-COVID symptoms from patients' electronic health records (EHR, n=564) and a randomized collection of Reddit and Twitter posts (n=500 for each). We show the inconsistencies in what types of symptoms are shared between platforms in addition to assessing the severity of the symptoms and how social media characterizations of post-COVID do not tell a complete story of this phenomenon. This research contributes to CSCW health literature by connecting digital traces of post-COVID with EHR data, critiquing the use of social media as a health proxy and points to its potential to add context to the analysis of traditional health data extracted from the EHR. © 2023 ACM.

Respiratory syncytial virus and Streptococcus pneumoniae Co-infection in an elderly individual within a familial cluster

Respiratory syncytial virus (RSV) is a common pathogen that causes respiratory tract infection and has been found to co-infect with other bacteria. Although the virus can cause morbidity and mortality in the elderly, RSV-bacteria co-infection had rarely been reported. In this paper, we reported the case of an elderly woman with RSV and Streptococcus pneumoniae co-infection in a familial cluster during the COVID-19 pandemic era. The patient was treated appropriately and showed complete recovery.Copyright © 2023 Wolters Kluwer Medknow Publications. All rights reserved.

YOLO-R Based Mask Recognition System with Winograd Convolution Acceleration Chip

In this paper, we proposed 'YOLO-R based mask recognition system with Winograd convolution acceleration chip.' In order to prevent the spread of COVID-19, we proposed a mask recognition system based on YOLO-R that adopted the CSP backbone architecture and used prediction refinement to predict, optimize, and obtain high recognition results. In addition, we designed the Winograd convolution acceleration chip to accelerate the operation of the YOLO-R neural network, so that the system can achieve real-time computing. © 2022 IEEE.

Composition decipherment of Ficus pumila var. awkeotsang and its potential on COVID-19 symptom amelioration and in silico prediction of SARS-CoV-2 interference

The jelly from achenes of Ficus pumila var. awkeotsang (FPAA) is a famous beverage ingredient in Taiwan. In this work, ficumarin (1), a new compound was obtained from its twigs (FPAT) and elucidated with comprehensive spectroscopic data. The biosynthetic origin was proposed from the p-coumaroyl-CoA pathway. Alloxanthoxyletin, betulinic acid, and catechin were identified as the major and active constituents responsible for relieving neutrophilic inflammation by FPAT. Among them, the most potent alloxanthoxyletin was found to interact with PRO350 and GLU377 of human INOSOX. Further, Nrf2 activating capacity of the FPAT fraction and its coumarins was confirmed. With the analysis of LC-MS/MS data and feature-based molecular networking, coumarins were found as the dominant and responsible components. Notably, alloxanthoxyletin increased Nrf2 expression by up to 816.8 +/- 58% due to the interacting with the VAL561, THR560 and VAL420 residues of 5FNQ protein. COVID-19 Docking Server simulation indicated that pyranocoumarins would promisingly interfere with the life cycle of SARS-CoV-2. FPAT was proven to exert. Copyright © 2022 Taiwan Food and Drug Administration.

TIMELY FOLLOW-UP OF ABNORMAL CANCER SCREENING TEST RESULTS IN TWO LARGE PRIMARY CARE PRACTICE NETWORKS

BACKGROUND: Timely follow-up of abnormal cancer screening test results (“abnormal screens”) is critical but often not achieved. As part of an NCI funded intervention trial (mFOCUS: multilevel Follow-up of Cancer Screening, ClinicalTrials.gov NCT03979495), we report on abnormal screens that were identified and tracked to identify eligible patients overdue for study inclusion. While not anticipated when this study was conceived, the COVID-19 pandemic resulted in a larger than anticipated backlog of patients in need of follow-up of abnormal screens. METHODS: Patients in two primary care practice networks affiliated with Mass General Brigham who had an abnormal screen for breast, cervical or lung cancer were identified using computerized algorithms and then tracked for completion of appropriate follow-up based upon the cancer type and the severity of the abnormal result. Since the intervention was designed as a “fail safe” system, additional time (2-6 months depending on the severity of the abnormal screen) was added after the recommended follow-up interval. We report the number of abnormal screens by cancer type and severity of the abnormality and the number of patients who completed follow-up based upon guideline and expert recommendations. RESULTS: Patient tracking and enrollment started with abnormal screens for breast and lung on 8/24/2020 and cervical cancer on 10/16/2020. Enrollment ended for all abnormal screens on December 15, 2021. Over the study period, 4003 abnormal breast, 5214 abnormal cervical, and 478 abnormal lung screens were identified. High risk abnormalities were most common for cervical (51.7%, recommended colposcopy or endometrial biopsy), lung (22.6%, LRADS 4B, 4X or 5), and lowest for breast (0.4%, BIRADS 5). Rates of completing recommended follow-up of abnormal screens by cancer type and severity of the result are shown in the table. CONCLUSIONS: Maximizing the benefits of cancer screening requires the timely follow-up of abnormal screening results. Though likely exacerbated by the COVID-19 pandemic, we identified that timely completion of abnormal screens is often not achieved. Rates of completion varied by cancer type and the severity of the abnormal result but highlight the need for systems based, multi-level interventions to identify, report and track abnormal results.

Case report: Anti-p1 and AB blood group-A faux Para- Bombay

Background: Anti-P1 is a common antibody found in the sera of P2 donors, affecting one-quarter to two-thirds of those tested. Anti-P1 is an IgM isotype antibody that is frequently found as a weak cold agglutinin. Anti-P1 antibodies that are reactive at 37 Celsius or cause in vitro hemolysis are rare. With the exception of the rare Bombay phenotype, all red cells express the H antigen. The amount of H antigen on red cells is determined by an individual's ABO type since H antigen is the precursor to both A and B antigens. The expression of the H antigen is highest in group O and lowest in group A1B (O>A2 > B > A2B > A1 > A1B). We report a case of blood discrepancy mimicking Para-Bombay due to anti-P1 and weak H antigen expression in a 46-year-old Sarawak Malay blood donor during routine blood donor regrouping with an automated immunohematology analyser. She has history of COVID19 infection in September 2021 and she completed her 1st, 2nd and booster mRNA vaccine in November 2021. Her last pregnancy was 13 years ago, and she has no history of blood transfusions. Aims: To resolve blood group discrepancies detected when using an automated immunohematology analyser. To understand the possibility of interference from natural occurring cold-reacting red cell alloantibodies during indirect antiglobulin test blood grouping. To understand the possibility of false negative in forward grouping with anti-H antisera in donors with A1B blood group. Methods: Blood donor was typed for ABO and Rh by an automated immunohematology analyser with microplates. Serological methods for antibody detection and specification were done manually with column agglutination method (gel-card) and tube method. Results: Forward grouping of the donor's first sample with an automated analyser was strongly positive for Anti-A (4+), Anti-B (4+), Anti-AB (4+) and Anti-D (4+), while reverse grouping was also strongly positive for A1-cell (3+), B-cell (3+) and O-cell (4+). Manual serological methods with gel-card and tube method yielded similar results. Anti-H showed no reaction. The first sample was negative for Direct Coomb's test (DCT). The donor's second (repeat) sample using the manual serological method yielded similar results;however, reverse grouping repeated at 37 Celcius resulted in the cessation of reactions on known cells. Anti-H showed a 1+ reaction. Antibody screening was positive and proceeded to 11 panel antibody identification with Anti-P1 identified. DCT was negative in the second sample. (P1-) and Le(a-b+) are her phenotypes. Summary/Conclusions: Anti-P1 is commonly reported as cold reacting alloantibody in patients. In this case, a combination of strong reacting anti-P1 at room temperature and commonly low H antigen volume in A1B red cells lead to a false initial suggestion of Para- Bombay phenotype. Blood grouping discrepancies detected with automation should always be repeated manually.

[Analysis of relationship between distribution of pathogenic microorganisms in olfactory cleft and olfactory disorders among patients with upper respiratory inflammation during the prevention and control of COVID-19].

Objective: To explore the relationship between pathogens in the olfactory cleft area and olfactory disorders in patients with upper respiratory inflammation (URI) during the prevention and control of 2019 novel coronavirus disease (COVID-19). Methods: A total of 234 URI patients including acute upper respiratory infection, chronic rhinosinusitis (CRS), allergic rhinitis (AR) were continuously selected from September 2020 to March 2021 in Beijing Anzhen Hospital and 98 healthy adults were enrolled as controls. The secretions from the olfactory cleft of all subjects were collected with nasal swabs under nasal endoscopy. Multiple real-time fluorescent quantitative polymerase chain reaction detection method was used to detect nucleic acids of 33 types of respiratory pathogenic microorganism. Sniffin' Sticks olfactory test was performed on all patients with URI. URI patients with olfactory dysfunction were followed up for 9 (8, 10) months (M (Q1, Q3)). SPSS 20.0 software was used for statistical analysis. Results: Among the 98 controls, 9 (9.18%) were positive for pathogenic microorganisms, including 1 (1.02%) rhinovirus, 1 (1.02%) parainfluenza virus type 3, 3 (3.06%) enterovirus, 1 (1.02%) staphylococcus aureus and 3 (3.06%) Moraxella catarrhalis. Among the 234 URI patients, 111 (47.44%) had olfactory disorders and 123 (52.56%) had normal sense of smell. In the olfactory disorder group (111 cases), 38 cases (34.23%) were positive for pathogenic microorganisms, and 4 cases (3.60%) were mixed infection, including 11 cases of rhinovirus (9.91%), 5 cases of coronavirus 229E (4.50%), 2 cases of coronavirus OC43/NL63 (1.80%), 3 cases of parainfluenza virus type 1 (2.70%), 2 cases of enterovirus (1.80%), 1 case of influenza B virus type BV (0.90%), 11 cases of Staphylococcus aureus (9.91%), 7 cases of Moraxella catarrhalis (6.31%), and 1 case of Klebsiella pneumoniae (0.90%). In the normal smell group (123 cases), 18 cases (14.63%) were positive for pathogenic microorganisms, and 1 case (0.81%) was mixed infection, including 3 cases of rhinovirus (2.44%), 4 cases of coronavirus 229E (3.25%), 1 case of Influenza virus type 3 (0.81%), 3 cases of enterovirus (2.44%), 3 cases of Staphylococcus aureus (2.44%), 4 cases of Moraxella catarrhalis (3.25%), and 1 case of Klebsiella pneumoniae (0.81%). Univariate analysis between the two groups found that there were significant differences in the detection rate of pathogenic microorganisms, rhinovirus and Staphylococcus aureus between the groups (all P<0.05). The detection rate of parainfluenza virus type 1, Staphylococcus aureus, and rhinovirus were different between the patients with olfactory disorder and normal olfactory function in the three subgroups of acute upper respiratory tract infection, CRS and AR, respectively (χ2 value was 3.88, 4.53 and 4.73, respectively, all P<0.05). During the follow-up period, among the 111 patients with olfactory disorder, 71 (63.96%) patients' olfactory function returned to normal, 32 (28.83%) patients' olfactory function improved but not completely returned to normal, 8 (7.21%) patients' olfactory function did not improve. Conclusions: During the prevention and control of COVID-19, rhinovirus or Staphylococcus aureus infection or colonization of URI patients is closely related to olfactory disorders. Parainfluenza virus type 1 infection can cause relatively persistent olfactory disorders in patients with acute upper respiratory tract infection. Staphylococcus aureus and rhinovirus colonization are related to the occurrence of olfactory dysfunction in CRS and AR patients respectively.

Profile of SARS-CoV-2 antibodies in patients awaiting kidney transplantation

Purpose: Patients with end-stage kidney disease (ESKD) represent an extremely vulnerable group with many risk factors for adverse outcomes following SARSCoV- 2 infection. Key questions pertaining to ESKD patients awaiting transplantation include quantifying the rates of symptomatic & asymptomatic infection and determining if seroconverted patients have functional neutralising activity against SARS-CoV-2. The study of the immunological characteristics of COVID-19 in ESKD patients may help the design of an effective vaccination strategy against SARS-CoV-2 for potential transplant recipients. Methods: Serum samples were analysed by direct ELISA to detect anti-SARS-CoV-2 IgG antibodies using a recombinant Spike S11-530 subunit and Nucleocapsid protein (NP). Recombinant human anti-SARS-CoV-2 mAbs that bind to spike RBD and NP were used as positive controls. Neutralization potency against SARS-CoV-2 was measured using HIV-1 luciferase-based pseudotype assays. Titres of neutralising antibodies were calculated as 50% inhibitory dose (ID50), expressed as the highest dilution of plasma which resulted in 50% reduction of luciferase luminescence compared with controls. Results: 217 patients were on our wait-list as of May 2020 (115 receiving in-centre haemodialysis [ICHD], 41 on peritoneal dialysis and 61 pre-dialysis). 164 serum samples, of which 76% were obtained by June 2020 and coincided with the first peak of the pandemic in UK, were analysed. The observed seroprevalence of SARS-CoV-2 antibodies was 36% (95% CI 32-46). Seroconverted patients were more frail (median Clinical Frailty Scale score 3 [IQR: 3-4] vs 3 [IQR: 2-3];p=0.02), mostly from BAME background (76.3% vs 52.4%, p=0.04), had higher prevalence of diabetes (27.1% vs 12.4%;p=0.02), and received ICHD (84.7% vs 60%;p=0.006). Levels of anti-S1 and anti-NP SARS-CoV-2 IgG strongly correlated with ID50 (r=0.58, p<0.0001 and r=0.41, p=0.004, respectively). Peak CRP levels were correlated with ID50 (r=0.30;p=0.05). There were significant declines of S1 and NP antibody titres as well as neutralising activity by a median of 90 days. Conclusions: Analysis of SARS-CoV-2 antibodies and neutralising activity suggest robust functional responses are produced in infected ESKD patients, but titres wane significantly by 3 months. The level of functional immunity to SARS-CoV-2 in patients with ESKD may be used to risk stratify patients on national waiting-lists for renal transplantation and will help evaluate the efficacy of vaccination schedules in wait-listed patients once this becomes available.